SAB Biotherapeutics, Inc., (SABS) News
Filter SABS News Items
SABS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SABS News From Around the Web
Below are the latest news stories about SAB BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate SABS as an investment opportunity.
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor ConferenceConference to take place Feb. 6-9 in New YorkSIOUX FALLS, S.D., Jan. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics, will present at the 2023 BIO CEO & Investor Conference on |
SAB Biotherapeutics Gets Another $8.2 million from Department of Defense in Closeout SettlementBy Exec Edge Editorial Staff Immunotherapy-focused SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and development contract. The total settlement value has now reached $16.8 million received since November 2022 […] |
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD ContractSIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and develop |
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 DiabetesStudy shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filingSIOUX FALLS, S.D., Jan. 10, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies (hpAB) without the need for hu |
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech ShowcaseSIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that Alexandra Kropotova, MD, Executive Vice President and Chief Medical Officer, will deliver a presentation at the Biotech Showcase in San Francisco on Tuesday, Jan. 10 at 2:30 p.m |
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune DiseasesSIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today results from a project in collaboration with global biotechnology leader CSL (ASX: CSL), confirming that SAB’s DiversitAb™ platform can generate functional fully-human anti-idiotype polyclonal ant |
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San FranciscoSIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting, an investor conference that drives biotech innovation and global collaboration through pre |
Independent Director Jeffrey Spragens Just Bought 27% More Shares In SAB Biotherapeutics, Inc. (NASDAQ:SABS)Even if it's not a huge purchase, we think it was good to see that Jeffrey Spragens, the Independent Director of SAB... |
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common StockSIOUX FALLS, S.D., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced it has entered into a securities purchase agreement for the private placement of approximately 7.3 million shares of its common stock and warrants to purchase an equal number of common stock (the |
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 DiabetesStudy of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filingSIOUX FALLS, S.D., Nov. 21, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced SAB-142 is being progressed |